In 2019, researchers led by Stephen Dominy reported in Science Advances that gingipains, the protease toxins produced by Porphyromonas gingivalis, were present in the majority of Alzheimer's brains they examined. Gingipain levels tracked tau and ubiquitin pathology. The organism most closely tied to chronic periodontitis appeared to have travelled from the gum pocket to the hippocampus. Whether it acts as a driver or an opportunistic passenger remains contested. Even so, the finding forced a reconsideration of where systemic disease begins.

Precision prevention is fluent in ApoB, Lp(a), insulin dynamics and coronary calcium scoring. The mouth rarely appears in longevity workups, even though it is a mucosal interface colonised by roughly 700 bacterial species. In periodontitis, that interface becomes an ulcerated epithelial surface in continuous contact with the circulation. It is usually delegated to a separate profession, assessed on a separate schedule, and documented in records that seldom reach the physician managing cardiometabolic risk.

That separation is increasingly hard to justify. Periodontitis affects roughly 40 percent of American adults over 30, and severe periodontitis ranks among the most prevalent chronic conditions worldwide. This article examines three things: the mechanisms linking oral dysbiosis to atherosclerosis and neurodegeneration, the assessment tools that go beyond your gums look fine, and the interventions with credible evidence for reducing periodontal inflammation. Those same interventions may also lower the systemic inflammatory burden that periodontal disease feeds.

The mechanistic case starts with surface area. In generalised moderate-to-severe periodontitis, the ulcerated epithelium lining diseased pockets, quantified as periodontal inflamed surface area (PISA), can reach tens of square centimetres. That is effectively a chronic open wound, colonised by a dense anaerobic biofilm, with direct vascular access. Chewing and toothbrushing produce transient bacteraemias daily, and lipopolysaccharide leaks into circulation as low-grade metabolic endotoxaemia.

Three pathways converge on the arterial wall. The first is systemic inflammation: periodontitis raises CRP, IL-6 and TNF-α, and periodontal therapy measurably lowers them. The second is direct invasion: DNA from P. gingivalis and Aggregatibacter actinomycetemcomitans has been recovered from carotid and coronary plaques, and P. gingivalis can invade endothelial cells and accelerate foam-cell formation. The third is molecular mimicry: antibodies against bacterial heat-shock proteins cross-react with human HSP60 expressed on stressed endothelium.

The interventional data are suggestive but incomplete. A 2012 American Heart Association statement concluded that the association is independent of shared risk factors but that causation is unproven. In Tonetti's 2007 NEJM trial, intensive periodontal treatment first caused an acute inflammatory spike and transient endothelial dysfunction. By six months, however, flow-mediated dilation had improved significantly compared with controls. In diabetes, periodontal therapy reduces HbA1c by roughly 0.3 to 0.4 percentage points, comparable to adding a second oral agent.

The neurodegeneration hypothesis is more provocative. Gingipains cleave tau and ApoE, and oral P. gingivalis infection in mice produced brain colonisation and increased amyloid-β1-42. This fits the antimicrobial protection hypothesis, which proposes that amyloid-β functions partly as an innate immune peptide that entraps microbes. Proposed routes into the brain include haematogenous spread across an ageing blood-brain barrier, retrograde trigeminal transport, and sustained peripheral cytokine signalling that primes microglia.

Caution is warranted. Atuzaginstat (COR388), a gingipain inhibitor, missed its co-primary endpoints in the GAIN trial, and liver toxicity triggered an FDA clinical hold. A post hoc signal in participants with detectable salivary P. gingivalis DNA kept the hypothesis alive without confirming it. Mendelian randomisation studies remain mixed. The most defensible model treats periodontitis as a modifiable inflammatory amplifier layered onto existing cardiometabolic and neurodegenerative risk, rather than a single root cause.

Takeaway

Periodontitis need not be the cause of atherosclerosis or dementia to matter. A chronic inflammatory wound that you can measure and treat is exactly the kind of risk amplifier precision prevention exists to remove.

A visual inspection and a polish do not constitute periodontal assessment. The foundation is full-mouth periodontal charting: probing depth at six sites per tooth, clinical attachment loss, bleeding on probing, recession, furcation involvement and mobility. Healthy sulci typically probe at 3 mm or less. Pockets of 5 mm or more that bleed indicate active disease harbouring anaerobic pathogens. The absence of bleeding on probing has a negative predictive value above 90 percent for future attachment loss, making it a remarkably useful stability marker.

The 2017 AAP/EFP classification brought periodontology closer to precision medicine. Staging (I to IV) captures severity and complexity. Grading (A to C) estimates progression rate, partly from the ratio of radiographic bone loss to age. Grade modifiers explicitly include smoking of ten or more cigarettes daily and HbA1c of 7.0 percent or higher, both of which shift patients toward Grade C. Anyone serious about prevention should know their stage and grade, and ideally their PISA, which can be calculated directly from charting data.

Salivary diagnostics add a biological layer. Point-of-care tests for active matrix metalloproteinase-8 (aMMP-8) detect collagenolytic activity, potentially flagging tissue destruction before attachment loss becomes clinically measurable. PCR-based pathogen panels quantify specific organisms, including the red complex (P. gingivalis, Tannerella forsythia, Treponema denticola), A. actinomycetemcomitans and Fusobacterium nucleatum. These panels are most valuable in refractory or rapidly progressing cases, where they can guide adjunctive antimicrobial selection rather than leaving it to empirical guesswork.

Broader microbiome analysis is advancing quickly but remains immature. 16S rRNA sequencing profiles community composition, usually at genus level. Shotgun metagenomics resolves species, strains and functional genes, including nitrate-reductase capacity relevant to nitric oxide biology. The caveats are substantial. Saliva differs from subgingival plaque, samples vary from day to day, validated reference ranges do not exist, and relative-abundance data are compositional. Consumer kits are best treated as hypothesis-generating rather than diagnostic.

The highest-yield approach integrates oral and systemic data. Pair periodontal charting with hs-CRP, HbA1c, fasting insulin and lipid markers, then repeat both sets after periodontal therapy. Unexplained residual elevation in hs-CRP should prompt a periodontal evaluation as readily as a search for occult infection or visceral adiposity. A reasonable cadence for higher-risk individuals is full charting annually, with biomarker reassessment roughly three months after any active treatment, when inflammatory resolution should be evident.

Takeaway

Ask your dentist for your periodontal stage, grade and bleeding score as routinely as you would ask your physician for your ApoB. Data that never leave the dental chart cannot inform your systemic risk model.

Mechanical biofilm disruption remains the non-negotiable foundation. Cochrane evidence shows powered toothbrushes, particularly oscillating-rotating designs, reduce plaque by about 21 percent and gingivitis by about 11 percent over three months compared with manual brushing. Interdental cleaning matters more than most people appreciate. Correctly sized interdental brushes outperform floss for plaque and bleeding reduction where spaces allow, and water flossers are a reasonable alternative. A practical baseline is two minutes of powered brushing twice daily plus daily interdental cleaning.

Antiseptic mouthwash deserves more scrutiny than it gets. Chlorhexidine reduces gingivitis, but it also suppresses nitrate-reducing commensals such as Neisseria, Rothia and Veillonella. These bacteria drive the enterosalivary nitrate-nitrite-nitric oxide pathway. In a 2013 study by Kapil and colleagues, seven days of chlorhexidine lowered plasma nitrite and raised systolic blood pressure by several mmHg. Reserve potent antiseptics for short, targeted courses, and support nitrate-reducing communities with dietary nitrate from rocket, spinach and beetroot.

Established periodontitis requires professional treatment, not just better home care. Non-surgical periodontal therapy, meaning scaling and root planing, should be followed by supportive periodontal care every three to four months rather than the conventional six. The EFP's S3 guideline supports adjunctive systemic amoxicillin plus metronidazole in selected patients with Stage III to IV, Grade C disease, applied judiciously given stewardship concerns. Patients with established cardiovascular disease should have their dental and medical teams coordinate, given the transient inflammatory surge that follows intensive treatment.

Host modulation targets the inflammatory response rather than the bacteria alone. Sub-antimicrobial-dose doxycycline (20 mg twice daily) inhibits collagenolytic MMPs and is an approved adjunct to scaling. Small trials of omega-3 fatty acids combined with low-dose aspirin show additional pocket-depth reduction, consistent with the biology of specialised pro-resolving mediators. Probiotic Lactobacillus reuteri has modest adjunctive support. Glycaemic control and smoking cessation remain the most powerful systemic levers, because both directly shift periodontal grade and progression.

Finally, address the oral environment itself. Mouth breathing and untreated sleep apnoea dry the mucosa and favour dysbiosis. Medication-induced xerostomia, common with anticholinergics, antidepressants and some antihypertensives, reduces salivary buffering and antimicrobial defence. Frequency of fermentable carbohydrate exposure matters more than total quantity. The unifying principle is the same one that governs any precision protocol: measure, intervene, remeasure. Then judge success by resolved bleeding and normalised inflammatory markers, not by how clean your teeth feel.

Takeaway

The goal is not a sterile mouth but a resilient one. Disrupt pathogenic biofilm mechanically, preserve the commensals that make nitric oxide, and resolve inflammation rather than simply suppressing bacteria.

The mouth is the most accessible chronic inflammatory site in the body, and one of the least measured. Mechanistic data link periodontal pathogens to endothelial dysfunction, plaque biology and possibly neurodegeneration. Interventional trials show improvements in vascular function, glycaemic control and inflammatory markers when periodontitis is treated.

A practical protocol follows. Obtain full periodontal charting with stage, grade and bleeding score. Add salivary pathogen testing where disease is progressive or refractory. Track hs-CRP and HbA1c alongside periodontal parameters. Maintain powered brushing and interdental cleaning, avoid habitual antiseptic rinses, and eat nitrate-rich vegetables. Treat active disease professionally, followed by three-to-four-month maintenance and host modulation where indicated.

The broader lesson concerns integration. Prevention fails at the boundaries between specialties, where risk goes unmeasured because no one owns it. Bringing the mouth into the longevity model costs little and may remove a persistent inflammatory input.